De-risking prostate cancer screening with ClarityDX Prostate
ClarityDX Prostate builds upon the utility of clinical features and blood-based biomarkers to determine a patient’s risk of having aggressive prostate cancer. This empowers patients and their healthcare providers make more informed healthcare decisions.
Dr. John Lewis
CEO of Nanostics and Bird Dogs Chair of Translational Oncology at the University of Alberta
Recent News
Nanostics and OncoHelix Partner to Provide ClarityDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the Middle East
OncoHelix will now offer the validated ClarityDX Prostate Risk Score [...]
Nanostics and Protean Launch CDX Prostate for Men at Risk of Having Aggressive Prostate Cancer in the US
EDMONTON, Alberta--Nanostics Inc., a precision health company developing diagnostic [...]
Breakthrough test provides clarity for prostate cancer diagnosis
With support from the Canadian Cancer Society, Dr John [...]